Lipid Nanoparticle Market
完整報告名稱與涵蓋範圍
Lipid Nanoparticle Market Size, Share & Trends Analysis Report, By Application (mRNA Vaccines, siRNA Delivery, Gene Editing Payloads, Protein Replacement Therapies), By Lipid Component Type (Ionizable Lipids, PEGylated Lipids, Helper Phospholipids, Cholesterol & Sterol Lipids), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
Lipid nanoparticles have become the delivery vehicle of choice for nucleic acid medicines, encapsulating fragile RNA and DNA cargo in ionizable lipid shells that protect the payload in circulation and release it inside target cells. This market covers LNP formulation technologies, the specialised lipid excipients that compose them, formulation and encapsulation equipment, and associated development and manufacturing services, across applications spanning mRNA vaccines, siRNA therapeutics, gene editing payloads and protein replacement approaches.
Demand is anchored in the clinical validation delivered by approved mRNA vaccines and siRNA products, which converted LNP delivery from an academic curiosity into licensed pharmaceutical infrastructure. Pipeline breadth is now the principal growth engine, as in vivo CRISPR programmes, self-amplifying RNA constructs and individualised cancer vaccines all rely on LNP encapsulation. Technology trends include next-generation ionizable lipids engineered for extrahepatic targeting, biodegradable lipid chemistries that reduce accumulation, microfluidic mixing platforms that make encapsulation reproducible at scale, and efforts to improve thermostability so products escape frozen cold chains. Intellectual property around ionizable lipid structures remains a defining competitive feature, with licensing disputes shaping who can commercialise what.
North America leads on the concentration of RNA therapeutics developers, with Europe strong in lipid excipient production and Asia Pacific scaling both lipid supply and fill finish capability. The competitive field is specialised and partly consolidated around a small set of lipid chemistry owners, excipient manufacturers and formulation technology providers.
The InsightAce study provides US$ revenue forecasts across all application, lipid component, end user and regional segments for 2026-2035, alongside segment trend analysis, competitive landscape mapping and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticle Market Snapshot
Chapter 4. Global Lipid Nanoparticle Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis
5.1. Application & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
5.2.1. mRNA Vaccines
5.2.2. siRNA Delivery
5.2.3. Gene Editing Payloads
5.2.4. Protein Replacement Therapies
5.2.5. Other Nucleic Acid Therapeutics
Chapter 6. Market Segmentation 2: By Lipid Component Type Estimates & Trend Analysis
6.1. Lipid Component Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Lipid Component Type:
6.2.1. Ionizable Lipids
6.2.2. PEGylated Lipids
6.2.3. Helper Phospholipids
6.2.4. Cholesterol & Sterol Lipids
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Pharmaceutical & Biotechnology Companies
7.2.2. Contract Manufacturers & Formulation Service Providers
7.2.3. Academic & Research Institutes
Chapter 8. Lipid Nanoparticle Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Precision NanoSystems (Cytiva)
10.2. Evonik Industries AG
10.3. CordenPharma International
10.4. Merck KGaA
10.5. Croda International Plc (Avanti Polar Lipids)
10.6. NOF Corporation
10.7. Genevant Sciences
10.8. Acuitas Therapeutics
10.9. Arcturus Therapeutics
10.10. Polymun Scientific
10.11. Cayman Chemical Company
10.12. Ardena Holding NV
圖表清單 List of Tables & Figures
Table 1. Global Lipid Nanoparticle Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 1. Lipid Nanoparticle Structure and Component Overview
Table 2. Global Lipid Nanoparticle Revenue Forecast by Lipid Component Type, 2026-2035 (US$ Mn)
Figure 2. Global Lipid Nanoparticle Share by Application, 2026 & 2035
Table 3. Global Lipid Nanoparticle Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Clinical Pipeline of LNP-Delivered Nucleic Acid Therapeutics by Phase
Table 4. North America Lipid Nanoparticle Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Ionizable Lipid Intellectual Property and Licensing Landscape
Table 5. Europe Lipid Nanoparticle Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Lipid Nanoparticle Growth Opportunity Analysis
Table 6. Asia Pacific Lipid Nanoparticle Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Microfluidic and Impingement Jet Mixing Technology Comparison
Table 7. Key Partnerships and Licensing Agreements in LNP Delivery
Figure 7. Competitive Positioning of Key Lipid Nanoparticle Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們